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Research
AbstrACt
Objective To investigate evolving patterns in 
antithrombotic treatment in UK patients with newly 
diagnosed non-valvular atrial fibrillation (AF).
Design Prospective, multicentre, international registry.
setting 186 primary care practices in the UK.
Participants 3482 participants prospectively enrolled in 
four sequential cohorts (cohort 2 (C2) n=830, diagnosed 
September 2011 to April 2013; cohort 3 (C3) n=902, 
diagnosed April 2013 to June 2014; cohort 4 (C4) n=850, 
diagnosed July 2014 to June 2015; cohort 5 (C5) n=900, 
diagnosed June 2015 to July 2016). Participants had 
newly diagnosed non-valvular AF and at least one risk 
factor for stroke, were aged ≥18, and provided informed 
consent. 
Main outcome measures Antithrombotic treatment 
initiated at diagnosis, overall and according to stroke and 
bleeding risks. Stroke risk was retrospectively calculated 
using CHA2DS2-VASc (cardiac failure, hypertension, 
age ≥75 (doubled), diabetes, stroke (doubled)–vascular 
disease, age 65–74 and sex category (female)) and 
bleeding risk using HAS-BLED (hypertension, abnormal 
renal/liver function (1 point each), stroke, bleeding 
history or predisposition, elderly (>65), drugs/alcohol 
concomitantly (1 point each)).
results 42.7% were women and the mean age was 
74.5 years. The median CHA2DS2-VASc score was 3 in 
all cohorts and the median HAS-BLED score was 2 in 
all cohorts. There was a statistically significant increase 
in the use of anticoagulant therapy from C2 to C5 (C2 
54.7%, C3 60.3%, C4 73.1%, C5 73.9%; P value for 
trend <0.0001). The increase in the use of anticoagulant 
was mainly in patients with CHA2DS2-VASc ≥2. The use 
of vitamin K antagonists (VKAs)±antiplatelet (AP) drugs 
decreased from C2 to C5 (C2 53.3%, C3 52.1%, C4 50.3%, 
C5 30.6%), while the use of non-vitamin K antagonist 
oral anticoagulants (NOACs)±AP increased (C2 1.3%, C3 
8.0%, C4 22.7%, C5 43.3%). The use of AP only decreased 
(C2 36.4%, C3 25.5%, C4 11.9%, C5 10.5%), as did the 
combination therapy of VKA+AP (C2 13.6%, C3 11.0%, C4 
9.6%, C5 5.8%).
Conclusion There has been a progressive increase in the 
proportion of patients newly diagnosed with AF receiving 
guideline-recommended therapy in the UK, potentially 
driven by the availability of NOACs.
trial registration number NCT01090362; Pre-results.
IntrODuCtIOn
Atrial fibrillation (AF) is a potent risk factor 
for stroke and mortality; people with AF 
have a fivefold increased risk of stroke and a 
twofold increased risk of death.1 2 AF-related 
strokes are more serious and are more likely 
to be fatal or lead to long-term disability than 
strokes in people without this arrhythmia.3 
Stroke prevention is therefore a principal 
goal in the treatment of AF4 and is a major 
public health priority.5 Fortunately, there 
are effective therapies, with anticoagulation 
shown to mitigate up to two-thirds of this 
stroke risk.
Since 2010, changes in treatment guide-
lines from the European Society of Cardi-
ology and the National Institute for Clinical 
Excellence (NICE) have widened the criteria 
for patients with AF that should be considered 
for antithrombotic therapy and now advocate 
strengths and limitations of the study
 ► This study describes real-world clinical practice in 
the UK for treatment initiated at atrial fibrillation (AF) 
diagnosis in patients with AF and at least one risk 
factor for stroke.
 ► Eligible patients were enrolled prospectively and 
consecutively without exclusions according to 
comorbidities or treatment.
 ► Patients were recruited in primary care in the 
UK, encompassing patients diagnosed in a 
comprehensive range of national care settings.
 ► This study does not include patients without capacity 
to consent.
 o
n
 2 M
ay 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-018905 on 13 January 2018. Downloaded from 
2 Apenteng PN, et al. BMJ Open 2018;8:e018905. doi:10.1136/bmjopen-2017-018905
Open Access 
anticoagulants (ACs) as the only appropriate antithrom-
botic therapy in patients with AF.4 5 ACs include vitamin 
K antagonists (VKAs; typically warfarin) and, recently, 
non-VKA oral anticoagulants (NOACs), comprising factor 
Xa inhibitors and direct thrombin inhibitors. Whereas 
the only anticoagulant previously recommended was 
warfarin, the updated AF guidelines from NICE include 
recommendations for NOACs for patients with non-val-
vular AF.
In 2014, NICE updated its guidelines on the manage-
ment of AF, recommending the CHA2DS2-VASc (cardiac 
failure, hypertension, age ≥75 (doubled), diabetes, stroke 
(doubled)–vascular disease, age 65–74 and sex category 
(female)) stroke risk tool for assessing stroke risk in 
patients with AF and further recommending anticoagula-
tion therapy for patients at high risk (CHA2DS2-VASc ≥2), 
a consideration of anticoagulant therapy for patients at 
moderate risk (CHA2DS2-VASc=1) and no anticoagulant 
or antiplatelet (AP) treatment for patients at low risk 
(defined as CHA2DS2-VASc=0 for men and CHA2DS2-
VASc=1 for women).5 In addition, the emergence of 
NOACs in the UK since 2012 has provided a wider range 
of AC options, particularly for patients for whom warfarin 
may not be appropriate. The change in guidelines 
coupled with the emergence of NOACs has the potential 
to transform clinical practice; however, the impact on 
the use of ACs in patients with AF in the UK is unclear.
More than 46 000 new cases of AF are diagnosed in 
the UK every year. Many studies have reported a long-
standing problem of undertreatment with ACs of patients 
at high risk of stroke6 7; UK studies in the last decade also 
report suboptimal treatment,8–11 though there is limited 
Table 1 Baseline characteristics of patients in cohorts 2 to 5
Variable
Cohort 2
(n=830)
(2011–2013)
Cohort 3
(n=902)
(2013–2014)
Cohort 4
(n=850)
(2014–2015)
Cohort 5
(n=900)
(2015–2016)
Total
C2 to C5
(n=3482)
Women, n/N (%) 376/850 (45.3) 391/902 (43.3) 343/850 (40.4) 378/900 (42.0) 1488/3482 (42.7)
Age at diagnosis, years, mean 
(SD)
75.2 (9.7) 73.8 (9.7) 74.2 (9.6) 74.8 (9.0) 74.5 (9.5)
Age at diagnosis, years, 
median (IQR)
77.0 (70.0 to 82.0) 75.0 (68.0 to 81.0) 75.0 (69.0 to 81.0) 75.0 (69.0 to 81.0) 75.0 (69.0 to 81.0)
Age group, n/N (%)
  <65 110/830 (13.3) 133/902 (14.7) 116/850 (13.6) 96/900 (10.7) 455/3482 (13.1)
  65–74 222/830 (26.7) 315/902 (34.9) 293/850 (34.5) 322/900 (35.8) 1152/3482 (33.1)
  ≥75 498/830 (60.0) 454/902 (50.3) 441/850 (51.9) 482/900 (53.6) 1875/3482 (53.8)
Caucasian race, n/N (%) 804/816 (98.5)a 867/884 (98.1)b 832/837 (99.4)c 853/860 (99.2)d 3356/3397 (98.8)e
Medical history, n/N (%)
  Congestive heart failure 70/830 (8.4) 69/902 (7.6) 56/850 (6.6) 57/900 (6.3) 252/3482 (7.2)
  Coronary artery disease 166/830 (20.0) 165/902 (18.3) 164/850 (19.3) 174/900 (19.3) 669/3482 (19.2)
  Acute coronary syndrome 87/830 (10.5) 74/896 (8.3)f 90/847 (10.6)g 89/897 (9.9)h 340/3470 (9.8)i
  Vascular disease 109/830 (13.1) 112/895 (12.5)j 125/848 (14.7)k 125/898 (13.9)l 471/3471 (13.6)m
  Systemic embolism 9/830 (1.1) 4/893 (0.4) 3/842 (0.4) 6/893 (0.7) 22/3458 (0.6)
  Stroke/TIA 101/830 (12.2) 105/902 (11.6) 116/850 (13.6) 106/900 (11.8) 428/3482 (12.3)
  History of bleeding 28/830 (3.4) 26/899 (2.9) 23/845 (2.7) 27/895 (3.0) 104/2574 (3.0)
  Hypertension 607/830 (73.1) 637/899 (70.9) 566/847 (66.8) 607/897 (67.7) 2417/3473 (69.6)
  Diabetes mellitus 136/830 (16.4) 156/902 (17.3) 168/850 (19.8) 154/900 (17.1) 614/3482 (17.6)
  Moderate to severe CKD* 244/830 (29.4) 241/902 (26.7) 199/850 (23.4) 196/900 (21.8) 880/3482 (25.3)
Risk scores
  CHA2DS2-VASc, median 
(IQR)
3.0 (2.0 to 4.0)n 3.0 (2.0 to 4.0)o 3.0 (2.0 to 4.0)p 3.0 (2.0 to 4.0)q 3.0 (2.0 to 4.0)r
  CHA2DS2-VASc, 0–1, n/N 
(%)
73/795 (9.2) 93/844 (11.0) 90/801 (11.2) 81/835 (9.7) 337/3275 (10.3)
  HAS-BLED, median (IQR) 2.0 (1.0 to 2.0)s 2.0 (1.0 to 2.0)t 2.0 (1.0 to 2.0)u 2.0 (1.0 to 2.0)v 2.0 (1.0 to 2.0)w
  HAS-BLED, 0–2, n/N (%) 437/574 (76.1) 510/641 (79.6) 535/638 (83.9) 524/615 (85.2) 2006/2468 (81.3)
Patients missing: a14, b18, c13, d40, e85, f6, g3, h3, i12, j7, k2, l1, m11, n35, o58, p49, q65, r207, s256, t261,  u212, v285, w1014.
*Includes NKF KDOQI stages III–V.
CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)–vascular disease, age 65–74 and sex category 
(female); CKD, chronic kidney disease; HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or 
predisposition, elderly (>65), drugs/alcohol concomitantly (one point each); NKF KDOQI, National Kidney Foundation’s Kidney Disease 
Outcomes Quality Initiative; TIA, transient ischaemic attack.
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evidence of AF management since the introduction of 
NOACs. Little is known about the contemporary real-
world management of patients newly diagnosed with AF 
who are perceived to be at risk of stroke by their physi-
cians. The Global Anticoagulant Registry in the FIELD–
Atrial Fibrillation (GARFIELD-AF) aims to determine 
real-life treatment patterns and clinical outcomes of 
patients with newly diagnosed non-valvular AF and at least 
one investigator-determined risk factor for stroke.12 13 This 
paper investigates the evolving patterns of antithrombotic 
treatment of UK patients enrolled in the GARFIELD-AF 
registry from September 2011 to July 2016.
MethODs
study design
GARFIELD-AF is an ongoing, prospective, non-inter-
ventional, international registry of adults (≥18 years) 
diagnosed with AF. Patients were recruited into five inde-
pendent cohorts; the first cohort also included a valida-
tion cohort of retrospective patients.
Participants
Inclusion criteria for the prospective cohort comprised a 
new diagnosis of non-valvular AF of up to 6 weeks prior to 
entry into the registry and an investigator-determined risk 
factor for stroke. Eligible patients were recruited consec-
utively at participating sites in order to prevent selec-
tion bias. The retrospective cohort comprised patients 
diagnosed 6–24 months before enrolment. Patients are 
followed up for a minimum of 2 years. Patients with tran-
sient AF, secondary to a reversible cause, and patients for 
whom follow-up was not possible were excluded from the 
registry. Full methods of the GARFIELD-AF registry have 
been previously reported.12 13
This paper reports baseline characteristics and treat-
ment patterns in UK participants enrolled into cohorts 
2 to 5; participants enrolled into cohort 1 were excluded 
as it consisted predominantly of a retrospective validation 
cohort.
setting
Enrolment of UK patients into cohorts 2 to 5 was under-
taken between September 2011 and July 2016 at 186 
general practices (GPs) across the UK (161 in England, 
8 in Wales, 8 in Northern Ireland and 9 in Scotland). 
The necessary regulatory approvals were obtained 
prior to recruitment, and all patients provided written 
informed consent prior to enrolment into the registry. 
The standard national diagnostic criteria for AF apply for 
GARFIELD-AF, and for the UK this was by electrocardio-
graphic confirmation.
Data sources
Data collected at baseline comprised demographics, body 
mass index, type of AF, care setting of diagnosis, treatment 
strategy initiated at diagnosis, reason for treatment deci-
sion and medical history. Data were collected through 
review of medical records by trained site staff using an 
electronic case report form.
Stroke risk was calculated retrospectively using 
CHA2DS2-VASc score-based variables: heart failure, hyper-
tension, age ≥75 years and 65–74 years, diabetes mellitus, 
prior stroke or transient ischaemic attack (TIA), left 
ventricular ejection fraction <40%, prior thromboem-
bolism, vascular disease and female gender. HAS-BLED 
scores were calculated retrospectively using the variables 
hypertension, abnormal renal/liver function, stroke, 
bleeding history or predisposition, elderly (>65) and 
drugs/alcohol concomitantly.
Data for the analysis in this report were extracted from 
the study database on 28 July 2016.
Definitions
ACs include VKAs and NOACs. NOACs include oral direct 
factor Xa inhibitors and oral direct thrombin inhibitors.
Vascular disease was defined as peripheral artery disease 
and/or coronary artery disease (CAD) with a history of 
acute coronary syndromes. Hypertension was defined 
as a documented history of hypertension or blood pres-
sure >140/90 mm Hg. Chronic kidney disease (CKD) 
was classified according to the National Kidney Founda-
tion’s Kidney Disease Outcomes Quality Initiative (NKF 
KDOQI) guidelines14: moderate to severe includes stages 
III to V; none or mild includes all other patients.
statistical analysis
Patient characteristics and medical history are described 
by cohort. Continuous variables are expressed as number 
of patients and mean±SD and or median and IQR. Cate-
gorical variables are expressed as frequencies and percent-
ages. Treatment patterns were analysed by cohort, and by 
cohort and CHA2DS2-VASc or HAS-BLED. Trends were 
assessed using an extension of the Wilcoxon rank-sum 
test.
Logistic regression models were used to assess the 
risk factors associated with the prescribing of NOACs 
(vs VKA). The following risk factors were included in 
the model: gender, age group, race, smoking, conges-
tive heart failure, hypertension, diabetes, CAD, vascular 
disease, dementia, moderate to severe CKD, non-ste-
roidal anti-inflammatory drug (NSAID) usage, history of 
bleeding, previous stroke/TIA/systemic embolism (SE) 
and cohort. ORs with 95% CIs were estimated to describe 
the associations of the risk factors and prescribing of 
NOACs versus VKA, as well as AP and no treatment (No 
ACs) versus ACs.
Multiple Imputation by Chained Equations was used to 
fill in missing values, creating five complete datasets.15 16 
Logistic regression was performed using the imputed data-
sets. First-degree interaction between comorbidities and 
time (cohort) was tested using likelihood ratio tests. Only 
significant interactions were included in the final model.
Statistical analysis was performed using both SAS soft-
ware V.9.4 (SAS Institute, Cary, NC, USA) and Stata Statis-
tical Software V.14 (StataCorp, College Station, TX, USA).
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results
Patient distribution and characteristics
In the UK, 3482 patients were enrolled into cohorts 2 to 
5 between September 2011 and July 2016: cohort 2 (C2) 
consisted of 830 patients diagnosed with AF between 
September 2011 and April 2013, cohort 3 (C3) consisted 
of 902 patients diagnosed between April 2013 and June 
2014, cohort 4 (C4) consisted of 850 patients diagnosed 
between July 2014 and June 2015, and cohort 5 (C5) 
consisted of 900 patients diagnosed between June 2015 
and July 2016. Overall, 42.7% of patients were women, 
mean age (SD) at diagnosis was 74.5 years (9.5) and 
89.7% had a CHA2DS2-VASc score of ≥2 (table 1).
Participants were diagnosed in a broad range of care 
settings representative of those in the UK: more than 
half of the patients (2124/3482; 61.0%) were diag-
nosed in primary care. The remainder were diagnosed 
in internal (general) medicine (21.9%), cardiology 
(15.2%), geriatrics (1.8%) and neurology (0.1%). Of 
the 3482 participants, 1370 (39.3%) had new or unclas-
sified AF, 640 (18.4%) had paroxysmal AF, 272 (7.8%) 
had persistent AF and 1200 (34.5%) had permanent AF. 
There were some variations in baseline characteristics 
across the four cohorts (table 1), though the median 
CHA2DS2-VASc and HAS-BLED scores were similar.
Antithrombotic therapy use by cohort
Figure 1 shows the treatment patterns at diagnosis in 
each of the four cohorts. The proportion of patients 
prescribed AC therapy at diagnosis, with or without 
an AP, increased consistently from C2 to C5 (54.7%, 
60.3%, 73.1% and 73.9%; for trend <0.0001), whereas 
the use of AP only decreased (36.4%, 25.5%, 11.9% 
and 10.5%). At the same time, there was an increase 
in the proportion of patients receiving NOACs with 
or without AP from C2 to C5 (1.3%, 8.1%, 22.7%, 
43.3%); the proportion of patients not receiving any 
antithrombotic therapy increased from C2 to C4 (8.9%, 
14.4%, 15.1%) then stayed similar in C5 (15.7%). 
Co-prescription of AC and AP was variable (C2 14.0%, 
C3 11.8%, C4 11.4%, C5 11.7%). Table 2 shows 
selected baseline characteristics for all patients (C2 to 
C5 combined) according to treatment group. Patients 
receiving no treatment generally had a lower inci-
dence of comorbidities, apart from history of bleeding; 
however, patients aged ≥75 years were more likely not to 
receive treatment.
Overall, 19.1% (666/3482) of patients were 
prescribed NOACs. Table 3 shows the baseline charac-
teristics of patients on NOACs by cohort. There were no 
clear patterns of NOAC use by patient characteristics; 
however, patients diagnosed in cardiology in the earlier 
cohorts were more likely to be given NOACs than those 
in the later cohorts, while among patients diagnosed 
in primary care the later cohorts were more likely to 
receive NOACs than earlier cohorts. Of the patients 
prescribed either NOACs or VKA, those with dementia 
were significantly more likely to receive NOACs than 
VKA compared with patients without a history of the 
condition (table 4). Also, patients were more likely to 
receive NOACs over VKA as the cohorts progressed, 
from C2 to C5; however, no interaction between cohort 
and covariates was statistically significant.
Table 5 shows the baseline characteristics of patients 
who received no AC therapy (34.3%, 1195/3482) by 
cohort. There were no clear changes over time in ‘no 
AC’ use when considering individual patient character-
istics. Nevertheless, in the whole population, ‘no AC’ 
was less likely (relative to AC therapy) in patients aged 
65–80 years, with diabetes, or a history of vascular disease 
and previous stroke/TIA/SE than in patients without 
these conditions or other age groups (table 6). ‘No AC’ 
was more likely if patients had a history of bleeding or 
with NSAID usage. Over time, UK physicians became 
increasingly less likely to choose ‘no AC’ with each 
successive cohort of patients enrolled between 2011 
and 2016.
Antithrombotic therapy use according to risk score
Figure 2 shows the use of antithrombotic therapy 
according to CHA2DS2-VASc score and cohort. Notably, 
the registry includes a few patients classified as low risk 
according to the CHA2DS2-VASc score (ie, 0 for men, 1 
for women) because the determination of risk factors 
was left to the clinician’s judgement and not prespec-
ified in the protocol. The use of AC±AP increased 
from C2 to C4 for patients at all levels of stroke risk 
(low, moderate and high risk), though the increase 
was highest in patients with a CHA2DS2-VASc of ≥2 (C2 
56.7%; C4 75.6%). At the same time, there was a decline 
in the proportion of patients receiving AP only and an 
increase in the proportion of high-risk patients not 
receiving any antithrombotic therapy. The overall use 
of antithrombotic therapy decreased in patients with 
low risk of stroke from C2 to C4, driven by a decline in 
the use of AP only from 35.7% in C2 to 11.8% in C4. 
Figure 1 Antithrombotic treatment at diagnosis by 
cohort. AP, antiplatelet; DTI, direct thrombin inhibitor; FXaI, 
factor Xa inhibitor; VKA, vitamin K antagonist.
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Also, the proportion of low-risk patients not receiving 
any antithrombotic therapy increased from 21.4% to 
35.3%. There was a slightly different pattern from C4 to 
C5; there was a decrease in the use of AC±AP in patients 
at low risk (C4 53.0%, C5 40.0%) and C5 had the largest 
proportion of low-risk patients not receiving treatment 
(50.0%). C5 saw an increase in NOAC use across all 
stroke risk levels, along with a decrease in the use of 
VKA.
Figure 3 shows the use of antithrombotic therapy 
according to HAS-BLED score and cohort. There was an 
increase in AC use over the study period for patients with 
a HAS-BLED score of 0 to 2; notably, there was a steady 
increase in AC±AP use in patients with HAS-BLED ≥3, 
peaking at C4 (C2 40.1%, C3 46.7%, C4 66.0%, C5 58.2%) 
at the expense of AP use.
Main reason anticoagulant was not used in patients with 
ChA2Ds2-VAsc ≥2
The main reasons why ACs were not used in patients with 
a CHA2DS2-VASc score of ≥2 are shown in table 7. The 
top two known reasons were patient refusal and physi-
cian’s choice. Patient refusal was variable, and in the most 
recent cohort (C5), it accounted for 11.2% of high-risk 
patients not receiving AC. There were also some varia-
tions in the reasons for physicians choosing not to give 
high-risk patients ACs across the cohorts; the main reason 
in C2 was fall risk, whereas the main reason in C5 was 
bleeding risk.
DIsCussIOn
These findings from the UK cohort of the GARFIELD-AF 
registry indicate a progressive improvement in the 
Table 2 Baseline characteristics of patients in cohorts 2 to 5 by antithrombotic treatment type
Variable
None
(n=470)
AP alone
(n=725)
VKA alone
(n=1267)
NOAC alone
(n=587)
AC+AP
(n=425)
AC±AP
(n=2279)
Women, n (%) 201 (42.8) 291 (40.1) 565 (44.6) 262 (44.6) 167 (39.3) 994 (43.6)
Age, mean (SD) 73.3 (10.5) 75.3 (9.7) 74.2 (9.4) 75.0 (9.4) 74.7 (8.2) 74.5 (9.2)
Age 65–74, n (%) 153 (32.6) 217 (29.9) 430 (33.9) 198 (33.7) 150 (35.3) 778 (34.1)
Age ≥75, n (%) 227 (48.3) 417 (57.5) 676 (53.4) 319 (54.3) 234 (55.1) 1229 (53.9)
Medical history, n (%)
  Heart failure (any) 22 (4.7) 46 (6.3) 97 (7.7) 36 (6.1) 49 (11.5) 182 (8.0)
  Hypertension (any) 325 (78.1) 531 (77.7) 961 (79.2) 451 (80.0) 331 (80.3) 1743 (79.6)
  Diabetes mellitus 51 (10.9) 105 (14.5) 249 (19.7) 94 (16.0) 112 (26.4) 455 (20.0)
  Stroke 12 (2.6) 55 (7.6) 78 (6.2) 46 (7.8) 52 (12.2) 176 (7.7)
  Systemic embolism – 5 (0.7) 12 (1.0) 1 (0.2) 4 (1.0) 17 (0.8)
  CAD (any) 37 (7.9) 187 (25.8) 168 (13.3) 90 (15.3) 182 (42.8) 440 (19.3)
  Vascular disease 23 (4.9) 120 (16.6) 125 (9.9) 64 (10.9) 137 (32.5) 326 (14.4)
  History of bleeding 34 (7.3) 35 (4.9) 14 (1.1) 15 (2.6) 6 (1.4) 35 (1.5)
  Moderate to severe 
CKD* 
94 (20.0) 208 (28.7) 331 (26.1) 128 (21.8) 117 (27.5) 576 (25.3)
Risk scores
  CHA2DS2-VASc, mean 
(SD)
2.8 (1.4) 3.3 (1.5) 3.3 (1.4) 3.3 (1.4) 3.8 (1.5) 3.4 (1.4)
  CHA2DS2-VASc, 
median (IQR)
3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 4.0 (3.0 to 5.0) 3.0 (2.0 to 4.0)
  CHA2DS2-VASc, 0–1,  
n (%)
75 (18.1) 73 (10.8) 107 (8.9) 57 (10.1) 24 (5.9) 188 (8.6)
  HAS-BLED, mean 
(SD)
1.4 (0.9) 2.4 (0.8) 1.4 (0.8) 1.4 (0.8) 2.4 (0.8) 1.6 (0.9)
  HAS-BLED, median 
(IQR)
1.0 (1.0 to 2.0) 2.0 (2.0 to 3.0) 1.0 (1.0 to 2.0) 1.0 (1.0 to 2.0) 2.0 (2.0 to 3.0) 2.0 (1.0 to 2.0)
  HAS-BLED, 0–2, n (%) 249 (88.7) 306 (61.3) 855 (90.2) 398 (91.9) 193 (63.9) 1446 (85.8)
*Includes NKF KDOQI stages III–V.
AC, anticoagulant; AP, antiplatelet; CAD, coronary artery disease; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, 
stroke (doubled)–vascular disease, age 65–74 and sex category (female); CKD, chronic kidney disease; HAS-BLED, hypertension, abnormal 
renal/liver function (1 point each), stroke, bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each); NKF 
KDOQI, National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, 
vitamin K antagonist.
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clinical management of AF, with newly diagnosed at-risk 
patients with AF more often receiving guideline-rec-
ommended therapy. The proportion of patients on AC 
increased (C2 54.5%, C3 60.1%, C4 72.9%, C5 73.9%) 
and the increase in the use of AC was mainly in patients 
with CHA2DS2-VASc ≥2. There was a notable increase in 
the use of NOACs±AP (C2 1.3%, C3 8.0%, C4 23.0%, 
C5 43.3%), with the main increase in NOAC prescribing 
being driven by the prescribing of factor Xa inhibitors; 
C5 saw a change in VKA prescribing, with NOACs being 
prescribed in place of VKA. The use of AP only decreased 
(C2 36.5%, C3 25.3%, C4 11.9%, C5 10.5%); however, the 
co-prescription of AC+AP did not change much (C2 14%, 
C3 11.8%, C4 11.4%, C5 11.7%). AC use decreased with 
bleeding risk, with people with HAS-BLED ≥3 less likely 
to be anticoagulated; nevertheless, use of AC in patients 
with HAS-BLED ≥3 increased notably from 40.1% in C2 to 
the peak of 66.0% in C4.
In addition, there was a decline in AP use in patients at 
low risk, with a corresponding increase in the proportion 
of patients in this category not receiving any antithrom-
botic therapy. However, an important proportion of 
low-risk patients received AC over the period, with 50% of 
low-risk patients receiving AC in the most recent cohort. 
Table 3 Baseline characteristics of patients on NOACs by cohort
Variable
Cohort 2
(n=11)
Cohort 3
(n=73)
Cohort 4
(n=193)
Cohort 5
(n=389)
Total
C2 to C5
(n=666)
Female, n (%) 4 (36.4) 42 (57.5) 80 (41.5) 165 (42.4) 291 (43.7)
Age at diagnosis, years, mean (SD) 75.9 (10.3) 74.8 (9.2) 74.7 (10.1) 74.7 (9.0) 74.7 (9.4)
Age at diagnosis, years, median (IQR) 75.0 (69.0 to 86.0) 74.0 (69.0 to 81.0) 76.0 (68.0 to 82.0) 75.0 (69.0 to 81.0) 75.0 (69.0 to 82.0)
Age group, n (%)
  <65 2 (18.2) 8 (11.0) 30 (15.5) 43 (11.1) 83 (12.5)
  65–74 3 (27.3) 29 (39.7) 59 (30.6) 138 (35.5) 229 (34.4)
  ≥75 6 (54.5) 36 (49.3) 104 (53.9) 208 (53.5) 354 (53.2)
Care setting at diagnosis, n (%)
  Internal medicine 2 (18.2) 18 (24.7) 53 (27.5) 108 (27.8) 181 (27.2)
  Cardiology 4 (36.4) 11 (15.1) 21 (10.9) 59 (15.2) 95 (14.3)
  Neurology – – 1 (0.5) 1 (0.3) 2 (0.3)
  Geriatrics – 2 (2.7) 2 (1.0) 7 (1.8) 11 (1.7)
  Primary care/general practice 5 (45.5) 42 (57.5) 116 (60.1) 214 (55.0) 377 (56.6)
Medical history, n (%)
  Congestive heart failure 2 (18.2) 4 (5.5) 14 (7.3) 23 (5.9) 43 (6.5)
  History of hypertension 10 (90.9) 48 (65.8) 139 (72.8) 276 (71.1) 473 (71.3)
  Diabetes mellitus 2 (18.2) 9 (12.3) 35 (18.1) 69 (17.7) 115 (17.3)
  Stroke – 7 (9.6) 16 (8.3) 32 (8.2) 55 (8.3)
  Systemic embolism – – 1 (0.5) 2 (0.5) 3 (0.5)
  Coronary artery disease 1 (9.1) 11 (15.1) 43 (22.3) 73 (18.8) 128 (19.2)
  Vascular disease 1 (9.1) 7 (9.7)a 37 (19.3)b 50 (12.9) 95 (14.3)c
  History of bleeding – 3 (4.1) 2 (1.0) 11 (2.8) 16 (2.4)
  Moderate to severe CKD* – 26 (35.6) 47 (24.4) 70 (18.0) 143 (21.5)
Risk scores
  CHA2DS2-VASc, mean (SD) 3.3 (1.7) 3.3 (1.4)
d 3.4 (1.5)e 3.3 (1.4)f 3.3 (1.5)g
  CHA2DS2-VASc, median (IQR) 4.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0)
  CHA2DS2-VASc, 0–1, n (%) 2 (18.2) 7 (9.9) 19 (10.4) 37 (9.9) 65 (10.2)
  HAS-BLED, mean (SD) 1.2 (0.8)h 1.7 (0.8)i 1.5 (0.8)j 1.4 (0.8)k 1.5 (0.8)l
  HAS-BLED, median (IQR) 1.0 (1.0 to 2.0) 2.0 (1.0 to 2.0) 1.0 (1.0 to 2.0) 1.0 (1.0 to 2.0) 1.0 (1.0 to 2.0)
  HAS-BLED, 0–2, n (%) 6 (100) 52 (86.7) 129 (89.0) 255 (92.4) 442 (90.8)
Patients missing: a1, b1, c2, d2, e10, f16, g28, h5, i13, j48, k113, l179.
*Includes NKF KDOQI stages III–V.
CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)–vascular disease, age 65–74 and sex category 
(female); CKD, chronic kidney disease; HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history 
or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each); NKF KDOQI, National Kidney Foundation’s Kidney Disease 
Outcomes Quality Initiative; NOAC, non-vitamin K antagonist oral anticoagulant.
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For patients with a CHA2DS2-VASc score of 1, there was a 
notable increase in AC prescribing from C2 to C5 and a 
steep decline in the use of AP only.
Our findings are, to a large extent, consistent with 
changes in AF management guidelines. In the UK, NICE 
guidelines up until 2014 recommend that high-risk 
patients should be on warfarin, those at moderate risk 
should receive warfarin or aspirin, and low-risk patients 
should not be on warfarin (but could be prescribed 
aspirin).17 The current (2014) guidelines no longer 
recommend aspirin; patients should receive anticoagula-
tion or not.5 The notable increase in AC use and corre-
sponding decline in AP use fall within the guidelines; 
our data suggest patients that would have been given 
aspirin in earlier cohorts are now given AC, also that the 
increase in AC use is potentially driven by the availability 
of NOACs.
This is the first UK study to describe the reasons for not 
anticoagulating real-world patients in relation to stroke 
risk, and the findings corroborate our deduction that 
guidelines have influenced clinical practice. The data 
suggest that patient refusal (11.2% for high-risk patients 
in the most recent cohort) may be the main patient 
factor affecting rates of anticoagulation. There is little UK 
evidence on AC treatment rates in the post-VKA-only era; 
nevertheless, co-prescription of ACs and APs (15.1%) is 
higher than reported by Kassianos et al11 (11% initiated 
on ACs plus APs within 12 weeks of diagnosis of AF).
strengths and limitations
This study describes real-world clinical practice in the UK 
for treatment initiated at AF diagnosis in patients with AF 
and at least one risk factor for stroke. Recruiting patients 
from primary care captures patients regardless of the 
care setting of diagnosis, therefore providing a pool of 
patients representative of UK patients diagnosed with AF. 
Study sites sought to recruit consecutive eligible patients, 
thereby reducing the risk of selection bias. In addition, 
the 6-week period between diagnosis and enrolment 
minimises the risk of excluding deceased patients.
The study is subject to the limitations inherent to 
observational studies, although efforts were made to 
standardise definitions and reduce missing data. Ethical 
approval for the study does not cover patients without the 
capacity to consent. The data on low-risk patients need 
to be interpreted with caution due to the low numbers in 
the UK sample. Comorbidities are likely confounders in 
treatment strategies; however, these were not comprehen-
sively incorporated in this analysis.
Comparison with global GArFIelD-AF data
Evolving antithrombotic treatment patterns up to C4 for 
the global GARFIELD-AF population have previously 
been published18; our comparison is in relation to UK 
patients enrolled during the corresponding recruitment 
period (C2 to C4). Globally, a total of 34 170 patients 
were enrolled into C2 to C4 in 34 countries. UK patients 
were older than patients in the global study: mean age of 
74.7 years compared with 69.9 years in the global study.18 
UK patients had less heart failure (7.6% vs 19.8%), higher 
prevalence of CKD (26.5% vs 10.3%), but similar rates of 
Table 4 Use of NOACs in relation to baseline 
characteristics for patients on an AC at baseline
Variable
Cohorts 2 to 5
OR (95%  CI) 
Gender
  Female 1
  Male 0.90 (0.72 to 1.12)
Age (years)
  65 1
  65–80 0.66 (0.47 to 0.92)
  80–85 0.71 (0.48 to 1.07)
  >85 1.02 (0.66 to 1.59)
Medical history*
  Congestive heart failure 0.88 (0.58 to 1.34)
  Hypertension (history 
or >140/90 mm Hg) 1.23 (0.93 to 1.62)
  Diabetes 0.78 (0.59 to 1.02)
  Coronary artery disease 1.14 (0.80 to 1.65)
  Vascular disease 1.14 (0.76 to 1.71)
  Dementia 3.58 (1.15 to 11.15)
  Moderate to severe CKD† 0.85 (0.65 to 1.10)
  NSAID usage 0.57 (0.44 to 0.74)
  Bleeding 1.90 (0.86 to 4.19)
  Previous stroke/TIA/SE 1.29 (0.96 to 1.75)
Smoking
  Never 1
  Ex-smoker 1.03 (0.82 to 1.29)
  Current smoker 0.61 (0.38 to 0.97)
Cohort
  2 1
  3 6.14 (3.28 to 11.52)
  4 7.24 (9.43 to 31.53)
  5 55.21 (30.29 to 100.62)
*Reference group is patients with no history of disease (for 
congestive heart failure, hypertension, diabetes, coronary artery 
disease, vascular disease, dementia, moderate to severe CKD, 
NSAID usage, bleeding, previous stroke/TIA/SE).
†Includes NKF KDOQI stages III–V; none or mild (reference group) 
includes all other patients.
An  OR  > 1  implies  that NOACs are more frequent than VKAs, 
while an  OR  < 1  means  that VKAs are more frequent than 
NOACs. No interaction between cohort and covariates was 
statistically significant. 
AC, anticoagulant; CKD, chronic kidney disease; NKF KDOQI, 
National Kidney Foundation’s Kidney Disease Outcomes Quality 
Initiative; NOAC, non-vitamin K antagonist oral anticoagulant; 
NSAID, non-steroidal anti-inflammatory drug; SE, systemic 
embolism; TIA, transient ischaemic attack; VKA, vitamin K 
antagonist.
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coronary artery disease and acute coronary syndromes. 
UK patients had a higher proportion of those with 
CHA2DS2-VASc score of 0–1 (10.5% vs 14.7%) and a lower 
proportion with HAS-BLED of 0–2 (81.3% vs 88.7%).
Despite starting from a lower baseline, the use of 
AC in the UK in the most recent cohort is compa-
rable to that in the global study (UK 54.7% to 73.1%, 
global 62.1% to 71.1%).18 Nevertheless, the uptake of 
NOACs is higher in the global study, with NOACs being 
prescribed in place of VKA, whereas VKA prescribing 
in the UK hardly changed up until C4 (NOAC use in 
C4: global 37.2%, UK 22.7%). In C5, however, UK data 
illustrate a decline in VKA prescribing matched by an 
increase in NOAC use. As in the UK population, over-
treatment of patients at low risk of stroke was observed 
in the global population, and over 50% of low-risk 
patients in C4 received AC. This may be due to clini-
cians’ perception of stroke risk as all participants were 
deemed by the recruiting clinician to have an investiga-
tor-determined risk factor for stroke. Co-prescription of 
AC+AP was also an issue in the global population, with 
6.8% affected in C4; however, the UK seems to have 
responded better to the renunciation of AP only as a 
treatment option: in C4, 11.7% of high-risk UK patients 
were given AP only compared with 16.0% in the global 
population.
Table 5 Baseline characteristics of patients not on AC by cohort
Variable
Cohort 2
(n=375)
Cohort 3
(n=356)
Cohort 4
(n=229)
Cohort 5
(n=235)
Total
C2 to C5
(n=1195)
Women, n (%) 166 (44.3) 140 (39.3) 89 (38.9) 97 (41.3) 492 (41.2)
Age at diagnosis, years, mean (SD) 75.2 (9.8) 74.0 (9.9) 73.8 (10.7) 74.9 (9.9) 74.5 (10.0)
Age at diagnosis, years, median (IQR) 77.0 (69.0 to 82.0) 75.0 (69.0 to 81.0) 74.0 (68.0 to 81.0) 75.0 (69.0 to 82.0) 75.0 (69.0 to 82.0)
Age group, n (%)
  <65 51 (13.6) 60 (16.9) 38 (16.6) 32 (13.6) 181 (15.1)
  65–74 102 (27.2) 114 (32.0) 78 (34.1) 76 (32.3) 370 (31.0)
  ≥75 222 (59.2) 182 (51.1) 113 (49.3) 127 (54.0) 644 (53.9)
Care setting at diagnosis, n (%)
  Internal medicine 66 (17.6) 73 (20.5) 49 (21.4) 37 (15.7) 255 (18.8)
  Cardiology 54 (14.4) 53 (14.9) 30 (13.1) 29 (12.3) 166 (13.9)
  Neurology – – 1 (0.4) 1 (0.4) 2 (0.2)
  Geriatrics 7 (1.9) 8 (2.2) 3 (1.3) 4 (1.7) 22 (1.8)
  Primary care/general practice 248 (66.1) 222 (62.4) 146 (63.3) 164 (69.8) 780 (65.3)
Medical history, n (%)
  Congestive heart failure 25 (6.7) 18 (5.1) 10 (4.4) 15 (6.4) 68 (5.7)
  History of hypertension 269 (71.7) 245 (68.8) 135 (59.2) 141 (60.3) 790 (66.2)
  Diabetes mellitus 46 (12.3) 50 (14.0) 29 (12.7) 31 (13.2) 156 (13.1)
  Stroke 23 (6.1) 20 (5.6) 7 (3.1) 17 (7.2) 67 (5.6)
  Systemic embolism 2 (0.5) 2 (0.6) – 1 (0.4) 5 (0.4)
  Coronary artery disease 80 (21.3) 57 (16.0) 44 (19.2) 43 (18.3) 224 (18.7)
  Vascular disease 46 (12.3) 34 (9.6)a 31 (13.5) 32 (13.7)b 143 (12.0)c
  History of bleeding 23 (6.1) 19 (5.4) 13 (5.7) 14 (6.0) 69 (5.8)
  Moderate to severe CKD* 108 (28.8) 82 (23.0) 47 (20.5) 65 (27.7) 302 (25.3)
Risk scores
  CHA2DS2-VASc, mean (SD) 3.2 (1.5)
d 3.0 (1.4)e 3.0 (1.5)f 3.2 (1.5)g 3.1 (1.5)h
  CHA2DS2-VASc, median (IQR) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0) 3.0 (2.0 to 4.0)
  CHA2DS2-VASc, 0–1, n (%) 41 (11.6) 46 (13.8) 34 (16.5) 27 (13.4) 148 (13.5)
  HAS-BLED, mean (SD) 2.2 (0.9)i 2.1 (0.9)j 1.7 (1.0)k 1.9 (1.1)l 2.0 (1.0)m
  HAS-BLED, median (IQR) 2.0 (2.0 to 3.0) 2.0 (2.0 to 3.0) 2.0 (1.0 to 2.0) 2.0 (1.0 to 3.0) 2.0 (1.0 to 3.0)
  HAS-BLED, 0–2, n (%) 164 (66.6) 173 (71.1) 122 (77.7) 96 (71.6) 555 (71.2)
Patients missing: a1, b1, c2, d22, e24, f22, g34, h102, i129, j113, k72, l101, m415.
*Includes NKF KDOQI stages III–V.
AC, anticoagulant; CHA2DS2-VASc, cardiac failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled)–vascular disease, age 65–74 
and sex category (female); CKD, chronic kidney disease; HAS-BLED, hypertension, abnormal renal/liver function (1 point each), stroke, 
bleeding history or predisposition, elderly (>65), drugs/alcohol concomitantly (1 point each), NKF KDOQI, National Kidney Foundation’s 
Kidney Disease Outcomes Quality Initiative.
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Implications for practice
These data indicate progressive concordance with 
evidence-based guidelines and clinical practice in the UK 
for patients newly diagnosed with AF. More UK patients 
are receiving guideline-recommended therapy; this is 
significant, given the increasing prevalence of AF in the 
UK. Although the proportion of high-risk patients taking 
an AC in the most recent cohort is unprecedented, nearly 
a quarter of high-risk patients still do not receive AC 
therapy, indicating that there is further scope for improve-
ment. It is important to elucidate the reasons why some 
high-risk patients do not receive anticoagulation; in partic-
ular, the reasons and circumstances for patient refusal 
need to be explored (and documented). An important 
proportion of low-risk patients are still receiving AC 
despite the proven capability of the CHA2DS2-VASc score 
to identify patients at truly low risk. Further attention to 
Table 6 Use of antiplatelet and no treatment (no AC) 
versus anticoagulant in relation to baseline characteristics
Variable
Cohorts 2 to 5
OR (95%  CI) 
Gender
  Female 1
  Male 1.09 (0.91 to 1.30)
Age (years)
  <65 1
  65–80 0.70 (0.54 to 0.90)
  80–85 0.75 (0.55 to 1.02)
  >85 0.98 (0.70 to 1.36)
Medical history*
  Congestive heart failure 0.73 (0.52 to 1.03)
  Hypertension (history or 
>140/90 mm Hg) 0.89 (0.72 to 1.09)
  Diabetes 0.57 (0.45 to 0.72)
  Coronary artery disease 0.84 (0.64 to 1.11)
  Vascular disease 0.63 (0.46 to 0.87)
  Dementia 0.72 (0.28 to 1.84)
  Moderate to severe CKD† 0.92 (0.75 to 1.12)
  NSAID usage 5.85 (4.89 to 7.00)
  Bleeding 6.30 (3.90 to 10.18)
  Previous stroke/TIA/SE 0.47 (0.36 to 0.62)
Smoking
  Never 1
  Ex-smoker 0.96 (0.81 to 1.15)
  Current smoker 1.04 (0.73 to 1.48)
Cohort
  2 1
  3 0.84 (0.67 to 1.05)
  4 0.55 (0.43 to 0.70)
  5 0.52 (0.41 to 0.66)
*Reference group is patients with no history of disease (for 
congestive heart failure, hypertension ,diabetes, coronary artery 
disease, vascular disease, dementia, moderate to severe CKD, 
NSAID usage, bleeding, previous stroke/TIA/SE)
†Includes NKF KDOQI stages III–V; none or mild (reference group) 
includes all other patients.
 Please note: An OR > 1 implies that No ACs are more frequent 
than ACs, while an OR < 1 means that ACs are more frequent than 
No ACs. Odds ratios were adjusted for all variables in the model. 
AC, anticoagulant; CKD, chronic kidney disease; NKF KDOQI, 
National Kidney Foundation’s Kidney Disease Outcomes Quality 
Initiative; NSAID, non-steroidal anti-inflammatory drug; SE, 
systemic embolism; TIA, transient ischaemic attack. 
Figure 2 Antithrombotic treatment at diagnosis by 
CHA2DS2-VASc and cohort, for patients with a score of 0, 1 
and ≥2. *Includes women with no other risk factors. The total 
population represented by n excludes unknowns. Patients 
with missing CHA2DS2-VASc score: C2, 35; C3, 58; C4, 49; 
C5, 65. AP, antiplatelet; CHA2DS2-VASc, cardiac failure, 
hypertension, age ≥75 (doubled), diabetes, stroke (doubled)–
vascular disease, age 65–74 and sex category (female); 
DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; VKA, 
vitamin K antagonist.
Figure 3 Antithrombotic treatment at diagnosis by HAS-
BLED score and cohort, for patients with a score of 0–2 
and ≥3. AP, antiplatelet; DTI, direct thrombin inhibitor; FXaI, 
factor Xa inhibitor; HAS-BLED, hypertension, abnormal 
renal/liver function (1 point each), stroke, bleeding history or 
predisposition, elderly (>65), drugs/alcohol concomitantly 
(1 point each); VKA, vitamin K antagonist.
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patients in this category will be beneficial. Also, patients 
are being co-prescribed ACs and aspirin (11.7% of high-
risk patients in most recent cohort), a combination that 
is rarely indicated since it increases bleeding risk by over 
50%; it might be worth exploring the rationale for this in 
future research.
The clinical management of patients with AF is evolving 
and treatment outcomes will become clearer with time. 
GARFIELD-AF provides real-world data on evolving treat-
ment patterns, and further data will provide insight into 
corresponding treatment outcomes.
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